EANS-News: AGENNIX AG / Agennix AG Schedules Conference Call on November 18, 2010 to Discuss Third Quarter 2010 Financial Results

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

9-month report/Conference Call

Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and
Houston, TX, October 28, 2010 - Agennix AG (Frankfurt Stock Exchange:
AGX) today announced that the Company will hold a conference call to
discuss financial results for the third quarter and first nine months
of 2010 and to provide a business update. The results will be
published on Thursday, November 18, 2010 in advance of the conference
call. Please note that this date is a change from the previously
announced date of November 4, 2010.

The conference call, which will be conducted in English, will be held
on Thursday, November 18, 2010 at 9 AM ET/3 PM CET.

A live webcast will be available on the Agennix Web site at
www.agennix.com. A replay will be available via the Web site
following the live event.

Dial-in numbers for the call are as follows:

Participants from Europe: 0049 (0)69 71044 5598
0044 (0)20 3003 2666
Participants from the U.S.: 1 212 999 6659

Please dial in 10 minutes before the beginning of the call.

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company´s most advanced program is talactoferrin, an oral therapy
that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as
well as in severe sepsis. Talactoferrin is currently in Phase III
clinical trials in non-small cell lung cancer, and Agennix plans to
develop this program further for the treatment of severe sepsis.
Other clinical development programs include RGB-286638, a
multi-targeted kinase inhibitor in Phase I testing; the oral
platinum-based compound satraplatin; and a topical gel form of
talactoferrin for diabetic foot ulcers. Agennix´s registered seat is
in Heidelberg, Germany. The Company has three sites of operation:
Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas.
For additional information, please visit the Agennix Web site at
www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. Forward-looking
statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking
statements, even if new information becomes available in the future.

Agennix™ is a trademark of the Agennix group.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Agennix AG

Investor Relations & Corporate Communications

Phone: +49 (0)89 8565 2693

ir@agennix.com

In the U.S.: Laurie Doyle

Director, Investor Relations & Corporate Communications

Phone: +1 609 524 5884

laurie.doyle@agennix.com

Additional media contacts for Europe:

MC Services AG

Raimund Gabriel

Phone: +49 (0) 89 210 228 0

raimund.gabriel@mc-services.eu

Additional investor contact for Europe:

Trout International LLC

Lauren Williams, Vice President

Phone: +44 207 936 9325

lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade